← Back to Analyst Consensus 
DMRA Buy
Damora Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 16
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 1 reiterations from 1 firms
Next Earnings
Oct 30, 2026 (4 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Sep 29, 2026 | Wedbush | reiterate | Outperform → Outperform | — | 58% |
| Sep 25, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Jul 30, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| Jul 27, 2026 | Jefferies | initiate | — → Buy | — | 52% |
| Jul 21, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Jun 12, 2026 | Wedbush | reiterate | Outperform → Outperform | — | 58% |
| Jun 11, 2026 | HC Wainwright & Co. | initiate | — → Buy | — | 44% |
| May 28, 2026 | Wedbush | initiate | — → Outperform | — | 58% |
| Apr 24, 2026 | RBC Capital | initiate | — → Outperform | — | 55% |
| Mar 25, 2026 | Evercore ISI Group | initiate | — → Outperform | — | 58% |
| Feb 17, 2026 | UBS | initiate | — → Buy | — | 54% |
| Feb 17, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Jan 7, 2026 | Leerink Partners | initiate | — → Outperform | — | 51% |
| Dec 8, 2025 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Dec 1, 2025 | Guggenheim | initiate | — → Buy | — | 52% |
Price Target Trend
Jun 24, 2026 Oct 26, 2026
EPS Estimates
0y —
+1y —
+1q —
0q —
Cross-Platform Signals
No cross-platform signals in the last 90 days